Back to Search
Start Over
BRCA-mutant pancreatic ductal adenocarcinoma
- Source :
- Br J Cancer
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Despite continued research, pancreatic ductal adenocarcinoma (PDAC) remains one of the main causes of cancer death. Interest is growing in the role of the tumour suppressors breast cancer 1 (BRCA1) and BRCA2—typically associated with breast and ovarian cancer—in the pathogenesis of PDAC. Indeed, both germline and sporadic mutations in BRCA1/2 have been found to play a role in the development of PDAC. However, data regarding BRCA1/2-mutant PDAC are lacking. In this review, we aim to outline the specific landscape of BRCA-mutant PDAC, focusing on heritability, clinical features, differences between BRCA1 and 2 mutations and between germline and sporadic alterations, as well as established therapeutic strategies and those that are still under evaluation.
- Subjects :
- Cancer Research
Pancreatic ductal adenocarcinoma
endocrine system diseases
Mutant
Review Article
Germline
law.invention
Causes of cancer
Pathogenesis
Breast cancer
law
Humans
Medicine
Genetic Predisposition to Disease
Precision Medicine
skin and connective tissue diseases
Germ-Line Mutation
BRCA2 Protein
BRCA1 Protein
business.industry
medicine.disease
digestive system diseases
Pancreatic Neoplasms
Oncology
Mutation
Cancer research
Suppressor
Female
business
Carcinoma, Pancreatic Ductal
Subjects
Details
- ISSN :
- 15321827 and 00070920
- Volume :
- 125
- Database :
- OpenAIRE
- Journal :
- British Journal of Cancer
- Accession number :
- edsair.doi.dedup.....2710a667d42212de1e74d576b004185a